References: Xie et al
These conditions include metabolic syndrome [11, 12], diabetes [4], high blood pressure, atherosclerosis [13], ischemia-reperfusion injury [13], cancer [14, 15], and various neurodegenerative disorders [16]
Cohen O, Ronen O, Khafif A, Rodrigo JP, Simo R, Pace-Asciak P, Randolph G, Mikkelsen LH, Kowalski LP, Olsen KD, Sanabria A, Tufano RP, Babighian S, Shaha AR, Zafereo ME , Ferlito A
Nurs Clin North Am
In the phase 1b/2a clinical trial with amycretin, an unimolecular GLP-1, and amylin RA intended for OW SC use, the 125 individuals with overweight or obesity included in the study achieved an estimated body weight loss of 9.7% on 1.25 mg (20 weeks), 16.2% on 5 mg (28 weeks) and 22.0% on 20 mg following 36 weeks of treatment [127]
Injection Site Since Melanotan 2 is injected under the skin, minor irritation, redness, or itching at the injection site can occur